Aethlon Medical (NASDAQ:AEMD) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report sent to investors on Monday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a research note on Friday, November 15th.

Aethlon Medical Price Performance

NASDAQ AEMD opened at $0.74 on Monday. The stock has a market capitalization of $10.35 million, a price-to-earnings ratio of -0.26 and a beta of 1.61. The business’s fifty day moving average is $0.56 and its 200-day moving average is $0.45. Aethlon Medical has a one year low of $0.24 and a one year high of $1.88.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.